Milestone Scientific Reports Significant Revenue Growth in 2025
Milestone Scientific Reports Growth in Q2 Revenues
Milestone Scientific Inc. (MLSS), renowned for its innovative computerized drug delivery systems, is delighted to announce substantial progress in its financial performance for the second quarter of 2025. This period saw the company achieve a remarkable 25% increase in revenue, totaling $2.3 million, primarily driven by a significant surge in international dental sales.
Key Highlights from Leadership Statements
Neal Goldman, the Chairman of the Board, expressed optimism about the company's trajectory as they experienced a doubling of international sales year-over-year. He highlighted their impressive gross margin of 70%, which is a testament to the effectiveness of cost management within their high-margin dental segment. Goldman emphasized enhanced leadership within the company, introducing Eric Hines as their new CEO, whose expertise in steering successful organizations is expected to be pivotal.
CEO's Vision for Future Growth
Eric Hines conveyed his aspirations to amplify momentum across both dental and medical products. The company's strong foundation of direct sales and enhanced e-commerce presence will support this growth strategy. Hines also detailed the pivotal role of marketing campaigns tailored to drive the adoption of their STA system, designed for painless and accurate dental injections.
Advancements in Medical Technology
Milestone Scientific is making strides in the medical sector as well. This includes recent accomplishments such as securing Medicare Part B payment under CPT code 0777T across various regions and initial coverage from commercial insurers for their CompuFlo Epidural System. These developments help open up influential channels in the healthcare system, bolstering revenue streams.
Financial Overview for Q2 2025
The financial results for the second quarter ended June 30, 2025, demonstrate that revenues increased from approximately $1.9 million to $2.3 million. The company reported e-commerce and dental service revenue of roughly $1.3 million for this period. International revenues also witnessed a significant upturn, bringing in about $1 million, an increase of approximately $524,000 compared to the previous year.
Operating and Net Loss Insights
Despite the growth in revenue, Milestone Scientific recorded an operating loss of around $1.5 million. However, this is an improvement from $1.8 million in the second quarter of 2024. The net loss reported was approximately $1.5 million, or $0.02 per share, compared to a profit of $0.2 million, or $0.00 per share, in 2024. This variation was mainly attributed to a notable sale of New Jersey net operating losses (NOL) in the previous year.
Strategic Outlook and Future Plans
Looking ahead, Milestone aims to consistently enhance its execution and broadening international outreach. Plans are in motion to expand their federal presence and tap into new markets through robust distribution partnerships. Hines is confident that their innovative technology and strategic focus will yield sustainable growth and create long-term shareholder value.
Conference Call Announcement
The company intends to host a conference call where executives will provide further insights into their financials and strategic initiatives, fostering transparent communication with stakeholders.
Company Overview
Milestone Scientific Inc. (MLSS) is at the forefront of medical research and development, creating cutting-edge injection technologies aimed at improving both medical and dental procedures. The company leverages its proprietary Dynamic Pressure Sensing Technology to enhance the precision and comfort of injections, thus ensuring superior patient safety.
Frequently Asked Questions
What was the revenue increase for Milestone Scientific in Q2 2025?
Milestone Scientific reported a 25% revenue increase, hitting $2.3 million.
Who is the new CEO of Milestone Scientific?
Eric Hines has been appointed as the new CEO, bringing extensive leadership experience.
What advancements has the company made in medical technology?
Milestone secured Medicare Part B payment for their CompuFlo Epidural System and gained coverage from commercial insurers.
What is Milestone Scientific's strategy for future growth?
The company plans to expand its federal presence and deepen market coverage through new partnerships while focusing on innovative technology.
How did Milestone Scientific perform compared to the previous year?
Compared to the previous year, Milestone experienced improved international revenue and operational loss, showcasing better management and strategy execution.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
